Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.45 |
| ▸ | EIF4H | Q15056 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924015 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23951476 | 0.86 | TACR1 (0.52) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28932974 | 0.86 | TACR1 (0.52) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23924239 | 0.84 | FABP7 (0.55) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23924250 | 0.84 | FABP7 (0.55) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23924238 | 0.84 | FABP7 (0.55) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23923839 | 0.84 | KDR (0.50) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23924263 | 0.84 | KDR (0.50) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23924412 | 0.83 | KDM4E (0.38) | ALDH1A1KDM4ESMN1; SMN2LMNAHTT | |
| SCHEMBL23924233 | 0.83 | KDM4E (0.38) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | ALDH1A1 2328/4885KDM4E 2961/4885MEN1 4081/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | ALDH1A1 2328/4885KDM4E 2961/4885MEN1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.